The Quality Lowdown: US FDA Finding New Crop Of Data Integrity Problems
Executive Summary
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.
You may also be interested in...
2020 In Review: Despite Pandemic, The US FDA Issued Just 20% Fewer Drug GMP Warning Letters
The US FDA managed to issue 94 drug GMP warning letters last year despite the pandemic, with fewer expected for 2021. Top issue areas included lack of sterility assurance, nitrosamine impurities, poor data integrity and basic GMP failures.
The Quality Lowdown: Warning Letters Suggest How The FDA Set Priorities During COVID-19
Calvin Scott, Acella Pharmaceuticals, Soluciones Cosmeticas and TAKA USA warning letters highlight issues with quality units, process control and specifications.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”